Comparison of side effects caused by common vaccines and Pfizer BioNTech COVID-19 (BNT162)

Douglas A. Drevets, MD, DTM&H, FIDSA

Internal Medicine/Infectious Diseases
University of Oklahoma Health Sciences Center
Oklahoma City, OK




Purpose

- Comparison of the reported side effects of BNT 162b2 with three, commonly used FDA approved vaccines
- Provide a quick look at the reported side effects of Pfizer's COVID-19 vaccine (BNT 162b2)

Background on BNT 162b2

mRNA vaccines give the immune system genetic instructions to recognise the virus




Scientists focus on the genetic sequence for the virus's 'spike' protein. This is used to synthesise an mRNA sequence – instructions that cells can use to make the 'spike' protein

The synthetic mRNA is packaged in a lipid nanoparticle that delivers the instructions to a cell

Once inside the cell, its cellular machinery follows the mRNA instructions to produce the viral protein. This is displayed on the surface of the cell and stimulates an immune system response

Cumulative Incidence Curves for the First COVID-19 Occurrence After Dose 1 – Dose 1 All-Available Efficacy Population




Materials

- Safety data were obtained from package inserts of 3 FDA approved vaccines
 - Seasonal Influenza
 - Fluzone® Quadrivalet (Sanofi Pasteur)
 - Fluzone ® High Dose Quadrivalet (Sanofi Pasteur)
 - Shingles (Varicella Zoster virus) reactivation
 - **Shingrix** (GlaxoSmithKline)
- COVID-19 vaccine (Pfizer-BioNTech)
 - BNT 162b2 versus Saline placebo
 - Documents used for data collection
 - FDA VRBPAC Briefing Document released 12/09/2020
 - Clinical Protocol C4591001 (Pfizer)


Methods

- Comparisons were made on data on adverse reactions in adult populations, but not all populations were of the same age.
 - Fluzone® Quadrivalet
 - Adults aged 18 and over
 - Half-aged 18-60 and half aged >61
 - Fluzone ® High Dose Quadrivalet
 - Adults aged 65 and over
 - Shingrix (GlaxoSmithKline)
 - Adults aged 50 and over
 - BNT162b2
 - Adults aged 16-55
 - Data comparing reactions in separate age groups are included separately

Local Reactions




Systemic Reactions




Participants Reporting Local Reactions, by Maximum Severity, Within 7 Days After Each Dose, by Age Group

Age Group 16-55 years



Age Group >55 years



Note: Number above each bar denotes percentage of subjects reporting the reaction with any severity.

PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (09:54) Source Data: adfacevd Table Generation: 17NOV2020 (16:40)


(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: /nda2_unblinded/C4591001_IA_P3_2MPD2/adce_f001_lr_max_age_p3

Note: Number above each bar denotes percentage of subjects reporting the reaction with any severity.


PFIZER CONFIDENTIAL SDTM Creation: 17NOV2020 (09:54) Source Data: adfacevd Table Generation: 17NOV2020 (16:40)

(Cutoff Date: 14NOV2020, Snapshot Date: 16NOV2020) Output File: /nda2_unblinded/C4591001_IA_P3_2MPD2/adce_f001_lr_max_age_p3

Participants Reporting Systemic Events, by Maximum Severity, Within 7 Days After Each Dose, Age Group 16-55 years



Participants Reporting Systemic Events, by Maximum Severity, Within 7 Days After Each Dose, Age Group >55 years




Observations

- Local side effects
 - BNT 162b2 hurts after administration.
 - Pain is similar to Shingrix (greater than flu vaccines), but evokes less swelling & redness than does Shingrix (comparable to HD flu vaccine)
- Systemic side effects
 - Are common with BNT 162b2 and are more common after the second dose than the first dose
 - Are a bit less common with BNT 162b2 in older than in younger age groups
 - Headache and malaise were the most common side effects, but were also fairly common in placebo
 - ~20-40% of adult subjects used anti-pyretics


Observations

- No one developed "Cows"
- There were 2
 "anaphlyactiod" reactions
 in the UK, successfully
 treated with self administered epi-pen.



Vaccine uptake: American's willingness to Receive COVID-19 Vaccination

If an FDA-approved vaccine to prevent coronavirus/COVID-19 was available right now at no cost, would you agree to be vaccinated?



Willingness to Be Vaccinated Against COVID-19, by Subgroup

Gender

Age

Education

Race/ethnicity

		Jul 20-26	Sep 14-27	Nov 16-29
Tota	al U.S. adults	66	50	63
Mei	n	65	56	66
Wo	men	67	44	60
18-4	44	68	60	68
45-6	64	62	36	52
65+		68	54	74
No	college degree	62	45	61
Coll	lege degree	75	60	68
Whi	ite adults	64	54	67
Nor	n-White adults	72	40	53

Looking ahead

- Distribution plans and logistics
- Uptake
- Safety data
 - Reactions not seen in 10,000 vaccinations will be found after >10,000,000 vaccinations
- Impact on educational programs and workforce
- Safety and Efficacy in special populations
 - Pregnant women
 - Children (<12)
 - Groups not included in the trials



KEEP GOING AND FINISH STRONG

